Pharmaceutical patent landscaping: A novel approach to understand patents from the drug discovery perspective

Gadiya, Yojana; Gribbon, Philip; Hofmann‐Apitius, Martin; Zaliani, Andrea

doi:10.1016/j.ailsci.2023.100069

Cited by 6 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The COVID-19 Pharamcome based approach by Schultz et al (2021) enabled the integration of existing data (both literature and experimental) on Sars-CoV-2 allowing for the identification of synergistic drug combinations like remdesivir-thioguanosine and nelfinavir-raloxifene. On the other hand, the applicability of the PEMT tool by Gadiya et al (2023B) focused on retrospective analysis of patent documents to identify the reasoning behind existing drug repurposing cases like Cleave Biosciences's CB-5083, from cancer to rare diseases, for its target specificity. Both these approaches emphasise the significance of adopting a legacy data perspective to inform future decisions in drug discovery.…”

Section: Fair Data and Drug Repurposingmentioning

confidence: 99%

FAIR data management: what does it mean for drug discovery?

Gadiya

Ioannidis

Henderson

et al. 2023

Front. Drug Discov.

Self Cite

View full text Add to dashboard Cite

The drug discovery community faces high costs in bringing safe and effective medicines to market, in part due to the rising volume and complexity of data which must be generated during the research and development process. Fully utilising these expensively created experimental and computational data resources has become a key aim of scientists due to the clear imperative to leverage the power of artificial intelligence (AI) and machine learning-based analyses to solve the complex problems inherent in drug discovery. In turn, AI methods heavily rely on the quantity, quality, consistency, and scope of underlying training data. While pre-existing preclinical and clinical data cannot fully replace the need for de novo data generation in a project, having access to relevant historical data represents a valuable asset, as its reuse can reduce the need to perform similar experiments, therefore avoiding a “reinventing the wheel” scenario. Unfortunately, most suitable data resources are often archived within institutes, companies, or individual research groups and hence unavailable to the wider community. Hence, enabling the data to be Findable, Accessible, Interoperable, and Reusable (FAIR) is crucial for the wider community of drug discovery and development scientists to learn from the work performed and utilise the findings to enhance comprehension of their own research outcomes. In this mini-review, we elucidate the utility of FAIR data management across the drug discovery pipeline and assess the impact such FAIR data has made on the drug development process.

show abstract

Section: Fair Data and Drug Repurposingmentioning

confidence: 99%

FAIR data management: what does it mean for drug discovery?

Gadiya

Ioannidis

Henderson

et al. 2023

Front. Drug Discov.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pharmaceutical-based patenting activity, which mainly covers claims related to a therapeutic design, synthesis, formulation, processing, and alternative usage or indications, reveals critical information pertaining to the development and prescription of drugs and biologics. In doing so, it serves as a valuable resource for understanding the landscape and dynamics of the pharmaceutical industry [5][6][7][8][9]. Pharmaceutical patents cover two fundamental components: the compound itself and its application [10,11].…”

Section: Introductionmentioning

confidence: 99%

Exploring SureChEMBL from a drug discovery perspective

Gadiya,

Shetty,

Hofmann-Apitius

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

In the pharmaceutical industry, the patent protection of drugs and medicines is accorded particular importance because of the high costs of research and development (R&D), associated with the considerable risks inherent in the creation of novel drugs. Consequently, patents play a pivotal role in ensuring a suitable return on R&D investments, especially those directed toward clinical trials. The patent corpus has been analyzed by researchers to identify freedom-to-operate spaces for novel drug candidates. Several well-established public patent data repositories have enabled automated methodologies for extracting information on therapeutic agents. In this manuscript, we delve into one such publicly available patent database, SureChEMBL, which catalogues patents related to life sciences. Our exploration begins by evaluating the coverage of compounds within SureChEMBL in comparison to other chemical data resources. Additionally, we pinpoint critical sections of patent documents where detailed chemical annotations can be found. Next, we exhibit the compounds’ potential to serve as drug candidates by evaluating their conformity to the Rule of Five (Ro5) and its extension, the beyond Ro5 (bRo5). Furthermore, we examine the development stage (preclinical or clinical) reported for these compounds as documented in public databases like ChEMBL. In summation, our investigation aims to provide an estimate of the relevance of the compounds catalogued within the SureChEMBL database in the context of the drug discovery domain.

show abstract

“…Pharmaceutical-based patenting activity, which mainly covers claims related to a therapeutic design, synthesis, and formulation, among others, reveals critical information pertaining to the development and prescription of drugs and biologics. In doing so, it serves as a valuable resource for understanding the landscape and dynamics of the pharmaceutical industry [5][6][7][8][9]. Pharmaceutical patents cover two fundamental components: the compound itself and its application [10,11].…”

Section: Introductionmentioning

confidence: 99%

Medicinal chemistry lens on patent data in SureChEMBL

Gadiya,

Shetty,

Hofmann-Apitius

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

In the pharmaceutical industry, the patent protection of drugs and medicines is accorded particular importance because of the high costs of research and development (R&D), associated with the considerable risks inherent in the creation of novel drugs. Consequently, patents play a pivotal role in ensuring a suitable return on R&D investments, especially those directed toward clinical trials. The patent corpus has been analyzed by researchers to identify freedom-to-operate spaces for novel drug candidates. Several well-established public patent data repositories have enabled automated methodologies for extracting information on therapeutic agents. In this manuscript, we delve into one such publicly available patent database, SureChEMBL, which catalogues patents related to life sciences. Our exploration begins by evaluating the coverage of compounds within SureChEMBL in comparison to other chemical data resources. Additionally, we pinpoint critical sections of patent documents where detailed chemical annotations can be found. Next, we exhibit the compounds' potential to serve as drug candidates by evaluating their conformity to the Rule of Five (Ro5) and its extension, the beyond Ro5 (bRo5). Furthermore, we examine the development stage (preclinical or clinical) reported for these compounds as documented in public databases like ChEMBL. In summation, our investigation aims to provide an estimate of the relevance of the compounds catalogued within the SureChEMBL database in the context of the drug discovery domain.

show abstract

Pharmaceutical patent landscaping: A novel approach to understand patents from the drug discovery perspective

Cited by 6 publications

References 50 publications

FAIR data management: what does it mean for drug discovery?

FAIR data management: what does it mean for drug discovery?

Exploring SureChEMBL from a drug discovery perspective

Medicinal chemistry lens on patent data in SureChEMBL

Contact Info

Product

Resources

About